BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 32629599)

  • 1. [Clinical application of the simultaneous detection of methotrexate and 7-hydroxymethotrexate in the delayed elimination for pediatric acute lymphoblastic leukemia].
    Luo GJ; Wang L; Hu GF; Li CB; Liu HX; Peng MT
    Zhonghua Yi Xue Za Zhi; 2020 Jul; 100(25):1973-1978. PubMed ID: 32629599
    [No Abstract]   [Full Text] [Related]  

  • 2. Plasma 7-Hydroxymethotrexate Levels Versus Methotrexate to Predict Delayed Elimination in Children Receiving High-Dose Methotrexate.
    Fabresse N; Devictor B; Pissier C; Chambost H; Lacarelle B; Michel G; Solas C
    Ther Drug Monit; 2018 Feb; 40(1):76-83. PubMed ID: 29120974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring of methotrexate and 7-hydroxymethotrexate in saliva from children with acute lymphoblastic leukemia receiving high-dose consolidation treatment: relation to oral mucositis.
    Albertioni F; Rask C; Schroeder H; Peterson C
    Anticancer Drugs; 1997 Feb; 8(2):119-24. PubMed ID: 9073308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose methotrexate in children with acute lymphoblastic leukemia: 7-hydroxymethotrexate systemic exposure and urinary concentrations at the steady state correlate well with those of methotrexate.
    Chládková J; Hak J; Martínková J; Chládek J
    Arzneimittelforschung; 2010; 60(12):769-75. PubMed ID: 21265469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral mucositis in children with acute lymphoblastic leukemia after high-dose methotrexate treatment without delayed elimination of methotrexate: relation to pharmacokinetic parameters of methotrexate.
    Rask C; Albertioni F; Schrøder H; Peterson C
    Pediatr Hematol Oncol; 1996; 13(4):359-67. PubMed ID: 8837142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue.
    Wolfrom C; Hepp R; Hartmann R; Breithaupt H; Henze G
    Eur J Clin Pharmacol; 1990; 39(4):377-83. PubMed ID: 2076721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interference of 7-hydroxymethotrexate with the determination of methotrexate in plasma samples from children with acute lymphoblastic leukemia employing routine clinical assays.
    Fotoohi K; Skärby T; Söderhäll S; Peterson C; Albertioni F
    J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Mar; 817(2):139-44. PubMed ID: 15686977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma levels of 7-hydroxymethotrexate after high-dose methotrexate treatment.
    Milano G; Thyss A; Renee N; Schneider M; Namer M; Boublil JL; Lalanne CM
    Cancer Chemother Pharmacol; 1983; 11(1):29-32. PubMed ID: 6883624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Creatinine clearance rate and serum creatinine concentration are related to delayed methotrexate elimination in children with lymphoblastic malignancies.
    Mao J; Zhang L; Shen H; Tang Y; Song H; Zhao F; Xu W
    Neoplasma; 2014; 61(1):77-82. PubMed ID: 24195512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and pharmacokinetic risk factors for high-dose methotrexate-induced toxicity in children with acute lymphoblastic leukemia--a logistic regression analysis.
    Rask C; Albertioni F; Bentzen SM; Schroeder H; Peterson C
    Acta Oncol; 1998; 37(3):277-84. PubMed ID: 9677100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal excretion and pharmacokinetics of methotrexate and 7-hydroxy-methotrexate following a 24-h high dose infusion of methotrexate in children.
    Winograd B; Lippens RJ; Oosterbaan MJ; Dirks MJ; Vree TB; van der Kleijn E
    Eur J Clin Pharmacol; 1986; 30(2):231-8. PubMed ID: 3709652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma creatinine as predictor of delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia: A Danish population-based study.
    Schmidt D; Kristensen K; Schroeder H; Wehner PS; Rosthøj S; Heldrup J; Damsgaard L; Schmiegelow K; Mikkelsen TS
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27637. PubMed ID: 30835935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trace analysis of methotrexate and 7-hydroxymethotrexate in human plasma and urine by a novel high-performance liquid chromatographic method.
    Beck O; Seideman P; Wennberg M; Peterson C
    Ther Drug Monit; 1991 Nov; 13(6):528-32. PubMed ID: 1771651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
    Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
    Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of clinical assays for measuring high-dose methotrexate in plasma.
    Albertioni F; Rask C; Eksborg S; Poulsen JH; Pettersson B; Beck O; Schroeder H; Peterson C
    Clin Chem; 1996 Jan; 42(1):39-44. PubMed ID: 8565230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL).
    Skärby T; Jönsson P; Hjorth L; Behrentz M; Björk O; Forestier E; Jarfelt M; Lönnerholm G; Höglund P
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):311-20. PubMed ID: 12721759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disparate mechanisms of antifolate resistance provoked by methotrexate and its metabolite 7-hydroxymethotrexate in leukemia cells: implications for efficacy of methotrexate therapy.
    Fotoohi K; Jansen G; Assaraf YG; Rothem L; Stark M; Kathmann I; Gregorczyk J; Peters GJ; Albertioni F
    Blood; 2004 Dec; 104(13):4194-201. PubMed ID: 15308564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia].
    Zhang H; He X; Li J; Wang Y; Wang C; Chen Y; Niu C; Gao P
    Zhonghua Er Ke Za Zhi; 2014 Oct; 52(10):770-6. PubMed ID: 25537545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia.
    Svahn T; Mellgren K; Harila-Saari A; Åsberg A; Kanerva J; Jónsson Ó; Vaitkeviciene G; Stamm Mikkelssen T; Schmiegelow K; Heldrup J
    Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 27966809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of 7-OH methotrexate metabolite on clinical relevance of methotrexate determination.
    Klapkova E; Kukacka J; Kotaska K; Suchanska I; Urinovska R; Prusa R
    Clin Lab; 2011; 57(7-8):599-606. PubMed ID: 21888024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.